Submitted:
29 March 2024
Posted:
01 April 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Design
2.1.1. Inclusion Criteria for Healthy and Diabetic Individuals
2.2. Patients with Renal Disease
2.2.1. Collection of Demographic and Clinical Data
2.2.2. Samples Collection

2.3. Biochemical Estimations
2.4. DNA Extraction and Quantification
2.4.1. Polymerase Chain Reaction (PCR) Amplification
2.4.1. Restriction Fragment Length Polymorphism (RFLP)
3. Results
3.1. Analysis of Demographic and Clinical Data
| S. No | Variables | Characteristics |
|---|---|---|
| 1 | Total Subjects | 260 |
| 2 | Age | 40-85 |
| 3 | Gender (M/F) | 90 (34.6%)/170 (65.3%) |
| 4 | Profession | Factory workers, Housewives |
| 5 | Income | Low income, upto PKR 20,000/month |
| 6 | Region | Lahore and its surrounding areas |
| 7 | Duration of Onset of Diabetes Range: 2-30 Years | Below 10 years: M: 52(25%), F:112(53.8%)=78.8 % Above 10 years: M: 20(9.6%), F: 24(11.5%)=20.7%. |
| 8 | Family History of Diabetes | Positive in M:8(3.8%), F:7(3.3%) = 7.1% |
| 9 | Physical Activity M/F | M:15(7.2%), F:10(4.8%) = 12.0% |
| 10 | Smoking | 30 males (14.4 %), one pack of 10 cigarettes/day.No shisha smokers. No female smokers |
| 11 | Diet | Oily parathas/bread and curry 2 times a day, Deep fried snacks once a day and less fibre |
| 12 | Alcohol | Nil |
| 13 | Treatment (Oral/Insulin or Both) | Oral: M:30 (14.4%), F:56(26.9%)=41.3% Insulin +oral: M:42(20.1%), F:80(38.4%)=58.5% |
| 14 | Hypertension (Systolic and Diastolic) | Range: (110/ 75)-(202/110) M:57(27.4 %), F:100(48.0 %)=75.4% |
| 15 |
BMI <25kg/m2 Below BMI >25kg/m2 Above |
Range: 19.6-36 M:13(6.2%) , F:2(0.9%) = 7% M: 59 (28.3%), F: 134(64.4%)=92.7% |
3.2. Characteristics of the Study Groups

3.3. Effect of Age on Hypertension
3.4. Effect of Duration of Diabetes on Hypertension
3.5. Onset of Diabetes in Study Subjects
3.6. Smoking
3.7. Biochemical Analysis

3.8. Blood Sugar Levels
3.9. HbA1c
3.10. Lipid Profile: Total Cholesterol
3.11. Total Triglycerides
3.12. Low Density Lipoproteins
3.13. High Density Lipoproteins
3.14. Very Low Density Lipoproteins

3.15. Serum Creatinine

3.16. Evaluation of Biochemical Parameters in Smokers and Non-Smokers in Study Groups
3.17. Restriction Analysis and Genotyping of Amplified DNA Product


3.18. Genotypic Distribution / Variation
4. Discussion
5. Conclusion
References
- Abdelbagi, O.; Musa, I.R.; Musa, S.M.; Altigani, S.A.; Adam, I. Prevalence and associated factors of hypertension among adults with diabetes mellitus in northern Sudan: a cross-sectional study. BMC Cardiovasc. Disord. 2021, 21, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Aljulifi, M.Z. Prevalence and reasons of increased type 2 diabetes in Gulf Cooperation Council Countries. SciVee 2021, 42, 481–490. [Google Scholar] [CrossRef]
- American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2019. Diabetes Care 2019, 42 (Supplement_1), S13–S28. [Google Scholar] [CrossRef] [PubMed]
- Bhupathiraju, S.N.; Hu, F.B. Epidemiology of Obesity and Diabetes and Their Cardiovascular Complications. Circ. Res. 2016, 118, 1723–1735. [Google Scholar] [CrossRef]
- Bommer, C.; Sagalova, V.; Heesemann, E.; Manne-Goehler, J.; Atun, R.; Bärnighausen, T.; Davies, J.; Vollmer, S. Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030. Diabetes Care 2018, 41, 963–970. [Google Scholar] [CrossRef] [PubMed]
- Campagna, D.; Alamo, A.; Di Pino, A.; Russo, C.; Calogero, A.E.; Purrello, F.; Polosa, R. Smoking and diabetes: dangerous liaisons and confusing relationships. Diabetol. Metab. Syndr. 2019, 11, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Chang, S.A. Smoking and Type 2 Diabetes Mellitus. Diabetes Metab. J. 2012, 36, 399–403. [Google Scholar] [CrossRef] [PubMed]
- Chen, R.; Ovbiagele, B.; Feng, W. Diabetes and stroke: epidemiology, pathophysiology, pharmaceuticals and outcomes. The American Journal of the Medical Sciences 2010, 351, 380–386. [Google Scholar] [CrossRef] [PubMed]
- Das, B.K.L.; Prassan, N.; Ansari, M.F.; Agrawal, K.; Tripathi, S.; Niraula, A. Dyslipidemic profile in Type 2 Diabetes Mellitus: A hospital-based study from Eastern Nepal. J. Biomed. Sci. 2020, 7, 64–70. [Google Scholar] [CrossRef]
- Einarson, T.R.; Acs, A.; Ludwig, C.; Panton, U.H. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc. Diabetol. 2018, 17, 1–19. [Google Scholar] [CrossRef]
- Gerdts, E.; Regitz-Zagrosek, V. Sex differences in cardiometabolic disorders. Nat. Med. 2019, 25, 1657–1666. [Google Scholar] [CrossRef]
- Huang, D.; Refaat, M.; Mohammedi, K.; Jayyousi, A.; Al Suwaidi, J.; Khalil, C.A. Macrovascular Complications in Patients with Diabetes and Prediabetes. BioMed Res. Int. 2017, 2017, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Huxley, R.; Barzi, F.; Woodward, M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2005, 332, 73–78. [Google Scholar] [CrossRef] [PubMed]
- Javed, R.A.; Bhatti, A.; AMIN, M. Dyslipidemia in type 2 diabetes mellitus in normal and underweight patient. Pak J Med Health Sci 2016, 10, 568–570. [Google Scholar]
- Kemche, B.; Foudjo, B.U.S.; Fokou, E. Risk Factors of Hypertension among Diabetic Patients from Yaoundé Central Hospital and Etoug-Ebe Baptist Health Centre, Cameroon. J. Diabetes Res. 2020, 2020, 1–8. [Google Scholar] [CrossRef]
- Liu, S.; Liu, J.; Weng, R.; Gu, X.; Zhong, Z. Apolipoprotein E gene polymorphism and the risk of cardiovascular disease and type 2 diabetes. BMC Cardiovasc. Disord. 2019, 19, 1–6. [Google Scholar] [CrossRef]
- Machado-Alba, J.E.; Machado-Duque, M.E. Cardiovascular risk factors prevalence among patients with dyslipidemia in Colombia. Revista Peruana de Medicina Experimental y Salud Publica 2013, 30, 205–211. [Google Scholar] [PubMed]
- Maqbool, T.; Awan, S.J.; Malik, S.; Hadi, F.; Shehzadi, S.; Tariq, K. In-Vitro Anti-Proliferative, Apoptotic and Antioxidative Activities of Medicinal Herb Kalonji (Nigella sativa). Curr. Pharm. Biotechnol. 2019, 20, 1288–1308. [Google Scholar] [CrossRef]
- Mansoor, G.; Tahir, M.; Maqbool, T.; Abbasi, S.Q.; Hadi, F.; Shakoori, T.A.; Akhtar, S.; Rafiq, M.; Ashraf, M.; Ullah, I. Increased Expression of Circulating Stress Markers, Inflammatory Cytokines and Decreased Antioxidant Level in Diabetic Nephropathy. Medicina 2022, 58, 1604. [Google Scholar] [CrossRef]
- Mehta, R.K.; Koirala, P.; Mallick, R.L.; Parajuli, S.; Jha, R. Dyslipidemia in Patients with Type 2 Diabetes Mellitus in a Tertiary Care Centre: A Descriptive Cross-sectional Study. J. Nepal Med Assoc. 2021, 59, 305–308. [Google Scholar] [CrossRef]
- Nilsson, P.M.; Tuomilehto, J.; Rydén, L. The metabolic syndrome – What is it and how should it be managed? Eur. J. Prev. Cardiol. 2019, 26, 33–46. [Google Scholar] [CrossRef]
- Peters, S.A.E.; Woodward, M. Sex Differences in the Burden and Complications of Diabetes. Curr. Diabetes Rep. 2018, 18, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Rasheed, M.; Islam, N.; Mahjabeen, W. Factors associated with uncontrolled type 2 diabetes mellitus. Journal of Islamabad Medical & Dental College (JIMDC) 2015, 4, 68–71. [Google Scholar]
- Reed, J.; Bain, S.; Kanamarlapudi, V. A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives. Diabetes, Metab. Syndr. Obesity: Targets Ther. 2021, 14, 3567–3602. [Google Scholar] [CrossRef] [PubMed]
- Riaz, F.; Al Shaikh, A.; Anjum, Q.; Alqahtani, Y.M.; Shahid, S. Factors related to the uncontrolled fasting blood sugar among type 2 diabetic patients attending primary health care center, Abha city, Saudi Arabia. Int. J. Clin. Pr. 2021, 75, e14168. [Google Scholar] [CrossRef] [PubMed]
- Sarfraz, M.; Sajid, S.; Ashraf, M.A. Prevalence and pattern of dyslipidemia in hyperglycemic patients and its associated factors among Pakistani population. Saudi J. Biol. Sci. 2016, 23, 761–766. [Google Scholar] [CrossRef]
- Seghieri, G.; Policardo, L.; Anichini, R.; Franconi, F.; Campesi, I.; Cherchi, S.; Tonolo, G. The Effect of Sex and Gender on Diabetic Complications. Curr. Diabetes Rev. 2017, 13, 148–160. [Google Scholar] [CrossRef]
- Shah, S.Z.A.; Karam, J.A.; Zeb, A.; Ullah, R.; Shah, A.; Haq, I.U.; Ali, I.; Darain, H.; Chen, H. Movement is Improvement: The Therapeutic Effects of Exercise and General Physical Activity on Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes Ther. 2021, 12, 707–732. [Google Scholar] [CrossRef] [PubMed]
- Tsenkova, V.K.; Karlamangla, A.S.; Ryff, C.D. Parental History of Diabetes, Positive Affect, and Diabetes Risk in Adults: Findings from MIDUS. Ann. Behav. Med. 2016, 50, 836–843. [Google Scholar] [CrossRef]
- Yan, Q.; Sun, D.; Li, X.; Chen, G.; Zheng, Q.; Li, L.; Gu, C.; Feng, B. Association of blood glucose level and hypertension in Elderly Chinese Subjects: a community based study. BMC Endocr. Disord. 2016, 16, 1–8. [Google Scholar] [CrossRef]
- Zhang, P.; Gao, J.; Pu, C.; Zhang, Y. Apolipoprotein status in type 2 diabetes mellitus and its complications. Mol. Med. Rep. 2017, 16, 9279–9286. [Google Scholar] [CrossRef] [PubMed]
| Variables |
Groups | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| C | D1 | D2 | D3 | D4 | ||||||
| Gender | M | F | M | F | M | F | M | F | M | F |
| Subjects | 18 | 34 | 18 | 34 | 18 | 34 | 18 | 34 | 18 | 34 |
| Age (years) | 48- 85 | 45- 85 | 45- 85 | 47- 87 | 48-75 | 48-85 | 61-85 | 50- 67 | 73- 80 | 54-76 |
| BMI (kg/m2) |
18.5- 22.9 |
19.5- 22.9 |
30.7- 33.7 |
27.5- 32.0 |
22.9- 32.0 |
21.0- 32.0 |
28.2- 32.5 |
22.1- 27.1 |
26-0- 32.0 |
21.0-28.2 |
| Systolic Blood Pressure (mmHg) |
110- 120 |
110- 120 |
135- 175 |
132- 202 |
155- 169 |
140- 172 |
140- 175 |
134- 160 |
144- 160 |
147- 165 |
| Diastolic Blood Pressure (mmHg) |
75- 79 |
75- 79 |
85- 100 |
85- 110 |
89- 100 |
88- 100 |
85- 100 |
80- 100 |
87- 100 |
85- 110 |
| Variables | C | D1 | D2 | D3 | D4 | P -Value | |
|---|---|---|---|---|---|---|---|
| Demographic | |||||||
| AGE (Years) | M | 72.40 ±11.22 |
64.00 ±17.81 |
66.60 ±16.16 |
76.40 ±8.00 |
77.00 ±7.88 |
0.762 |
| F | 65.60 ±17.42 |
63.00 ±17.81 |
65.40 ±17.35 |
59.40 ±19.4 |
65.40 ±14.09 |
0.762 | |
| BMI (kg/m2) | M | 20.22 ±0.81 |
30.72 ±1.19 |
25.38 ±1.29 |
31.04 ±0.79 |
29.36 ±0.96 |
0.0001 |
| F | 20.44 ±0.80 |
28.60 ±1.10 |
26.20 ±1.85 |
24.44 ±0.92 |
25.24 ±1.26 |
0.0001 | |
| Blood Pressure | |||||||
| Systolic Blood Pressure (mmHg) | M | 114.00 ± 1.70 |
151.80 ± 6.68 |
160.20 ±3.56 | 152.20 ±6.71 |
146.80 ±5.17 |
0.0001 |
| F | 112.60 ±1.32 |
157.80 ±11.78 | 154.20 ± 6.91 |
143.20 ±7.27 |
157.80 ±3.27 |
0.0001 | |
| Diastolic Blood Pressure(mmHg) | M | 77.00 ±0.70 |
93.60 ± 2.89 |
90.60 ±4.50 | 93.80 ±2.85 | 94.00 ±2.60 |
0.0001 |
| F | 77.00 ±0.70 |
97.00 ±4.03 | 91.00 ±4.15 | 91.80 ±3.55 |
95.60 ±1.72 |
0.0001 | |
| Blood Pressure Variation in Disease Group | |||||||||
| Stages of Hypertension | D1 | D2 | D3 | D4 |
Total % of Hypertensive Patients |
||||
| M | F | M | F | M | F | M | F | ||
| HTN Stage 1 | 1 | 0 | 3 | 5 | 4 | 3 | 6 | 5 | 14.9% (4.8% males , 10.1% females) |
| HTN Stage 2 | 3 | 22 | 5 | 5 | 6 | 5 | 60 | 55 | (60.5%) (18.75 % males, 41.8% females) |
| Normal Blood Pressure |
3 | 5 | 1 | 1 | 1 | 1 | 6 | 5 | (24.5%), (11.0 % males , 13.4% females) |
| Total | 4 | 2 | 8 | 10 | 10 | 8 | 66 | 60 | (75.4%) % males 27.4% females 48.0% |
| (12.29%) | (8.5%) | (8.5%) | (59.7%) | ||||||
| Age Group | Hypertension Stage | Percentages (%) | Total % of HTN Subjects |
|---|---|---|---|
| Age 40-60 | Stage 1 | 10 (4.8%) | (38.5%) |
| Stage 2 | 70 (33.6%) | ||
| No HTN | 6 (2.8%) | ||
| Age 60 Above | Stage 1 HTN | 18 (8.5%) | (36.9%) |
| Stage 2 HTN | 60 (28.4%) | ||
| No HTN | 37 (17.5%) |
| Duration | No HTN | HTN Stage 1 | HTN Stage 2 | Total |
|---|---|---|---|---|
| > 10 years Above | 0.8 % | 4.9 % | 16.0 % | 20.9 % |
| <10 years Below | 9.0 % | 5.4 % | 49.0 % | 54.4 % |
| Duration of Diabetes | Male Percentage | Female Percentage | Total Percentage |
|---|---|---|---|
| >10 Years Above | 20 (9.6%) | 24 (11.5%) | (21.1%) |
| <10 Years Below | 55 (26.4%) | 112 (53.8%) | (80.2%) |
| Variables | C | D1 | D2 | D3 | D4 | P-Value | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| smoker | non smoker |
smoker | non smoker |
smoker | non smoker |
smoker | non smoker |
smoker | non smoker |
||
|
Age (years) |
70.00 ±20.90 |
71.13 ±13.80 |
63.00 ±18.90 |
57.20 ±14.79 |
70.50 ±13.50 |
55.00 ±13.00 |
58.00 ±18.11 |
67.00 ±16.65 |
53.00 ±13.39 |
66.25 ±14.55 |
0.56 |
|
BMI (Kg/m2) |
19.99 ±0.79 |
20.00 ±0.80 |
28.68 ±1.62 |
29.52 ±0.73 |
31.85 ±0.65 |
26.40 ±0.70 |
26.53 ±2.18 |
28.76 ±1.16 |
28.20 ±1.05 |
24.95 ±1.11 |
0.05 |
|
Systolic Blood Pressure (mmHg) |
113.13 ±1.68 |
114.90 ±1.59 |
155.60 ±11.63 |
165.60 ±9.42 |
157.00 ±17.50 |
140.00 ±20.00 |
158.33 ±12.01 |
160.66 ±6.98 |
142.75 ±12.87 |
140.75 ±9.02 |
0.05 |
|
Diastolic Blood Pressure (mmHg) |
76.39 ±0.69 |
77.00 ±0.70 |
88.20 ±4.32 |
91.60 ±3.98 |
92.50 ±2.50 |
90.00 ±10.00 |
91.66 ±4.41 |
98.00 ±4.35 |
85.50 ±4.51 |
89.50 ±3.88 |
0.05 |
| Sr.no | Variables | Control | Diabetic mg/Dl |
|---|---|---|---|
| 1 | Blood Sugar Fasting (BSF) | < 126 mg/dL | 145-356mg/dL |
| 2 | Glycated Hemoglobin (HbA1c) | < 5.7 % | 6.8-13.6 % |
| 3 | Total Cholesterol (TC) | < 150mg/dL | 205-532mg/dL |
| 4 | Total Triglycerides (TG) | < 150mg/dL | 197-433 mg/dL |
| 5 | High Density Lipoproteins (HDL) | > 70-78 mg/dL | 36-58 mg/dL |
| 6 | Low Density Lipoproteins (LDL) | < 100 mg/dL | 137-255 mg/Dl |
| 7 | Very Low Density Lipoproteins (VLDL) | 2-30 mg/dL | 45-90 mg/dL |
| 8 | Serum Creatinine | < 0.5mg/dL | 0.4-1.1 mg/dL |
| Variables | C | D1 | D2 | D3 | D4 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| M | F | M | F | M | F | M | F | M | F | |
| Blood Sugar | ||||||||||
| Blood Sugar fasting mg/dL | 73- 87 |
73- 83 |
250- 326 |
260- 288 |
300- 339 |
287- 356 |
166- 225 |
145- 220 |
158- 185 |
148- 189 |
| HbA1c % |
4.3- 5.0 |
3.9-5.0 | 6.8- 8.8 |
9.6- 13.6 |
6.9- 8.1 |
7.8- 9.5 |
6.8- 8.9 |
7.3- 8.9 |
7.1- 8.4 |
7.6- 8.4 |
| Lipid Profile | ||||||||||
| TC mg/dL |
150- 170 |
160- 175 |
250- 277 |
205- 239 |
200- 250 |
210- 231 |
200- 250 |
217- 245 |
480- 532 |
214- 265 |
| TG mg/dL |
90- 100 |
90-100 | 410- 433 |
267- 277 |
220- 270 |
247- 285 |
210- 214 |
300- 379 |
197- 220 |
220- 340 |
| HDL mg/dL | 70- 78 |
70- 78 |
52- 58 |
40- 45 |
50- 55 |
37- 45 |
44- 46 |
36- 40 |
36- 40 |
41- 50 |
| LDL mg/dL | 80- 90 |
85- 90 |
132- 148 |
148- 165 |
176- 189 |
184- 198 |
167- 189 |
175- 178 |
238 - 255 |
179- 230 |
| VLDL mg/dL | 20- 30 |
25- 35 |
80- 86 |
49- 55 |
50- 57 |
47- 58 |
49- 55 |
65- 75 |
80- 90 |
80- 85 |
| Others | ||||||||||
| Serum Creatinine mg/dL | 0.7- 1.0 |
0.5-1.0 | 0.5- 1.1 |
0.5- 1.1 |
0.7- 1.0 |
0.5- 1.0 |
0.7- 1.0 |
0.5- 1.0 |
0.8- 1.0 |
0.7- 1.1 |
| Variables | C | D1 | D2 | D3 | D4 | P-Value | |
|---|---|---|---|---|---|---|---|
| Blood Sugar | |||||||
| BSF | M | 79.60 ±2.63 |
291.00 ±12.23 |
313.80 ±7.31 |
187.20 ±16.68 |
174.20 ±5.91 |
0.0001 |
| F | 81.40 ±2.80 |
281.00 ±7.29 |
326.60 ±12.48 |
184.20 ±14.75 |
166.00 ±7.59 |
0.0001 | |
| HbA1c | M | 4.40 ±0.23 |
7.62 ±0.40 |
7.58 ±0.26 |
7.74 ± 0.35 |
7.32 ±0.38 |
0.0001 |
| F | 4.48 ±0.22 |
11.50 ±0.69 |
8.16 ± 0.63 |
7.78 ±0.44 |
7.74 ±0.39 |
0.0001 | |
| Lipid Profile | |||||||
| TC | M | 120.00 ±5.00 |
263.500 ±13.500 |
225.000 ±25.000 |
225.000 ±25.000 | 506.00 ±26.00 |
0.0001 |
| F | 127.50 ±2.50 |
222.00 ±17.00 |
220.50 ±10.50 |
231.00 ±14.00 |
239.50 ±25.50 |
0.0001 | |
| TG | M | 100.00 ±0.00 |
421.50 ±11.50 |
245.00 ±25.00 | 212.00 ±2.00 |
208.50 ±11.50 |
0.0001 |
| F | 90.00 ±0.00 |
272.00 ± 5.00 |
266.00 ±19.00 |
339.50 ±39.50 |
280.00 ±60.00 |
0.0001 | |
| HDL | M | 74.40 ±4.00 |
55.00 ±3.00 |
52.50 ±2.50 |
45.00 ±1.00 |
38.00 ±2.00 |
0.0001 |
| F | 74.00 ±4.00 |
42.50 ±2.50 |
41.00 ±4.00 |
38.00 ±2.00 |
45.50 ±4.50 |
0.0001 | |
| LDL | M | 82.50 ±7.50 |
137.00 ±5.00 |
182.50 ±6.50 |
178.00 ±11.00 |
246.50 ±8.50 |
0.0001 |
| F | 85.00 ±5.00 |
156.50 ±8.50 |
191.00 ±7.00 |
176.50 ±1.50 |
204.50 ±25.50 |
0.0001 | |
| VLDL | M | 25.00 ±5.00 |
80.50 ±35.50 |
50.00 ±13.00 |
48.50 ±5.50 |
82.50 ±0.50 |
0.0001 |
| F | 31.50 ±3.50 |
52.00 ±3.00 |
51.50 ±5.50 |
70.50 ±4.50 |
82.50 ±2.50 |
0.0001 | |
| Others | |||||||
| Creatinine | M | 0.83 ±0.05 |
0.86 ±0.08 |
0.83 ±0.05 |
0.83 ±0.05 |
0.89 ±0.03 |
0.1614 |
| F | 0.72 ±0.08 |
0.90 ±0.07 |
0.72 ±0.08 |
0.72 ±0.08 |
0.90 ±0.03 |
0.1614 | |
| Variables. | Groups | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| C | D1 | D2 | D3 | D4 | P-Value | ||||||
| Smoker | Non Smoker |
Smoker | Non Smoker |
Smoker | Non Smoker |
Smoker | Non Smoker |
Smoker | Non Smoker |
||
| BSF | 77.62 ±2.61 |
76.43 ±2.59 |
252.40 ±34.71 |
205.60 ±8.54 |
186.50 ±19.50 |
189.50 ±6.50 |
193.00 ±29.87 |
173.00 ±32.45 |
190.25 ±11.80 |
198.75 ±12.21 |
0.001 |
| HbA1c | 4.52 ±0.34 |
4.46 ±0.31 |
8.12 ±0.46 |
7.90 ±0.27 |
7.20 ±0.10 |
7.60 ±1.25 |
7.83 ±0.31 |
7.16 ±0.61 |
7.52 ±0.31 |
7.42 ±0.33 |
0.001 |
| Creatinine | 0.83 ±0.06. |
0.80 ±0.07 |
0.70 ±0.07 |
0.70 ±0.10 |
1.00 ±0.10 |
0.70 ±0.10 |
0.83 ±0.17 |
0.70 ±0.05 |
0.750 ±0.06 |
0.55 ±0.06 |
0.10 |
| Total Cholesterol | 120.01 ±4.45 |
118.23 ±4.34 |
216.60 ±11.50 |
182.20 ±21.53 |
200.50 ±13.50 |
180.00 ±5.00 |
315.33 ±108.40 |
197.00 ±5.50 |
210.75 ±23.03 |
204.25 ±14.19 |
0.001 |
| Triglycerides | 99.78 ±0.01 |
100.09 ±0.43 |
179.00 ±7.05 |
176.80 ±21.59 |
197.50 ±0.50 |
283.50 ±95.50 |
166.00 ±18.50 |
234.33 ±52.96 |
254.25 ±61.05 |
206.75 ±26.94 |
0.05 |
| HDL | 73.45 ±3.38 |
73.65 ±3.32 |
43.80 ±3.18 |
38.00 ±2.62 |
45.00 ±1.00 |
38.00 ±2.00 |
38.33 ±1.20 |
43.33 ±0.66 |
51.000 ±9.65 |
56.50 ±8.05 |
0.01 |
| LDL | 81.45 ±7.00 |
80.91 ±6.72 |
161.80 ±10.78 |
156.60 ±18.27 |
183.00 ±5.00 |
159.00 ±19.00 |
195.00 ±30.55 |
183.00 ±25.35 |
143.50 ±4.368 |
133.00 ±15.98 |
0.001 |
| VLDL | 25.02 ±4.90 |
25.06 ±4.89 |
79/00 ±30.48 |
78.39 ±30.00 |
50.00 ±12.98 |
48.99 ±13.00 |
46.49 ±5.00 |
47.44 ±4.48 |
81.48 ±2.33 |
80.43 ±2.19 |
0.001 |
| Genotype | C | D1 | D2 | D3 | D4 | P-Value |
|---|---|---|---|---|---|---|
| E3/3 | 2(3.8%) | 10(19.2%) | 14(26.9%) | 12(23.0%) | 14(26.9%) | 0.0001 |
| E4/4 | 2(3.8%) | 7(13.4%) | 16(30.7%) | 10(19.2%) | 13(25%) | 0.0001 |
| E2/3 | 3(5.7%) | 6(11.5%) | 8(15.3%) | 12(23%) | 10(19.2%) | 0.0001 |
| E3/4 | 3(5.7%) | 8(15.3%) | 11(21.1%) | 13(25%) | 12(23.0%) | 0.0001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).